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Medication adherenceBackground: The burden of osteoporosis in the Asia-Paciﬁc region is not well characterized. The Medication Use
Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Paciﬁc Region (MUSIC
OS-AP) was designed to better understand the association of gastrointestinal events with patient-reported out-
comes in postmenopausal women of this region.
Methods:MUSIC OS-AP is a prospective, multinational, observational cohort study of postmenopausal women
≥50 years of age diagnosed with osteoporosis. The study was conducted in ﬁve Asia-Paciﬁc countries:
Australia, New Zealand, Taiwan, Korea, and India. MUSIC OS-AP has three components: a physician question-
naire, a retrospective chart review, and a prospective cohort study. The physician questionnaire investigated
the role of gastrointestinal events in physicians' pharmacologic management of osteoporosis. The retrospective
chart review, also completed byphysicians, recorded rate of osteoporosis treatment and the types of osteoporosis
medications prescribed to osteoporosis patients. The prospective cohort study investigated the associations be-
tween gastrointestinal events and patient-reported outcomes among patients taking oral medications for osteo-
porosis as well as reasons for non-treatment in patients who remained untreated.
The prospective cohort study enrolled two groups of patients: untreated, and treatedwith oral osteoporosismed-
ications. Untreated patients completed only the baseline surveys, providing informationon gastrointestinal event
rates, quality of life, health care resource use, and reasons for non-treatment. Treated patients, who were either
new to osteoporosis medication or continuing an ongoing medication course, completed surveys at baseline and
3, 6, and 12 months post-baseline. The evaluations recorded patient characteristics, gastrointestinal events,
health-related and osteoporosis-speciﬁc quality of life, health care resource use, medication adherence, and sat-
isfaction with treatment.
Results: Physicians at 59 sites completed the physician questionnaire, and data for 300 patients from26 siteswere
abstracted for the retrospective chart review. Enrollment and baseline data collection for the prospective cohort
studywere conducted between July 2013 andAugust 2014 for 301 untreated and 3287 treated patients, ofwhom
1416 were new users and 1871 were experienced users of oral osteoporosis medications.
Conclusions: The results of MUSIC OS-AP will highlight the association of gastrointestinal events with patient-
reported outcomes among postmenopausal women with osteoporosis and elucidate physicians' management
of gastrointestinal events among this patient population in the Asia-Paciﬁc region.
© 2015 Merck and company. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).orosis treatment; BMD, bonemineral density; EQ-5D-3L, EuropeanQuality of Life-5Dimensions; GI, gastrointestinal;MUSIC-OS,
dequate Control of Osteoporosis Study; OPAQ-SV, Osteoporosis Assessment Questionnaire; OPSAT-Q, Osteoporosis Patient
d Real-World Evidence (CORE), Merck & Co., Inc., 600 Corporate Drive, Mailstop: CRB-205, Kenilworth, NJ, USA.
evier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
62 A. Modi et al. / Bone Reports 3 (2015) 61–661. IntroductionThe prevalence of osteoporosis in older women (i.e., aged ≥50) liv-
ing in Asia-Paciﬁc countries is comparable to that in Europe and North
America (Wade et al., 2014), with values ranging from 23% in
Australia (Henry et al., 2011) to 38% in Korea (Park et al., 2014) and
50% or higher in India (Meeta et al., 2013). TheWorld Health Organiza-
tion found that, in the year 2000, approximately 45% of osteoporotic
fractures occurringworldwidewere in Southeast Asian andWestern Pa-
ciﬁc countries, including Australia, New Zealand, China, and Korea
(Johnell & Kanis, 2006).
Although osteoporosis is common in the Asia-Paciﬁc region,
information on the pharmacologic treatment of osteoporosis,
e.g., treatment rates, treatment satisfaction, and the effects of treatment
on health care resource use and quality of life, is scarce. In Australia, the
self-reported rate of pharmacologic treatment of osteoporosis in a
population-based sample aged ≥50 years was 54.1% (Gill et al., 2012),
and in Korea, the rate of administration of osteoporosis drugs to post-
menopausal women with physician-diagnosed osteoporosis was 42.1%
(Lee et al., 2014). Bisphosphonateswere themost commonly prescribed
pharmacotherapy in both studies (Gill et al., 2012; Lee et al., 2014), and
alendronate was the most commonly used bisphosphonate in the
Australian study (Gill et al., 2012). Beyond this, little is known about
themanagement of osteoporosis in Asia-Paciﬁc countries or about oste-
oporosis patients' experiencewith pharmacologic treatment. In particu-
lar, the gastrointestinal (GI) events that are so common among users of
osteoporosis therapy in US (Tosteson et al., 2003) and European (Ringe
& Moller, 2009; Payer et al., 2009) populations are virtually
uncharacterized in patients in the Asia-Paciﬁc region.
The Medication Use Patterns, Treatment Satisfaction, and Inadequate
Control of Osteoporosis Study in the Asia-Paciﬁc Region (MUSIC OS-AP)
was designed to address this information gap by querying physicians' ap-
proaches to treating patients with GI events, determining rates of phar-
macologic treatment and reasons for non-treatment, and assessing the
association of GI events with treatment patterns (i.e., adherence, persis-
tence, discontinuation, switching) and patient-reported outcomes
(i.e., treatment satisfaction, health care resource use, and quality of life)
in osteoporosis patients in the Asia-Paciﬁc region.Fig. 1. Design of MThe primary objectives of MUSIC OS-APwere to describe: (i) the fre-
quency of GI events among postmenopausal women receiving pharma-
cologic treatment for osteoporosis; (ii) the association between GI
events and adherence to, discontinuation of, and switching between os-
teoporosis medications; and (iii) the association between GI events and
health-related quality of life, treatment satisfaction, and health care re-
source utilization. Secondary objectives were: (i) to describe the
physician's approach to the management of osteoporosis patients with
GI events; (ii) to estimate the rates of pharmacologic treatment and
non-treatment of osteoporosis; and (iii) to determine the factors associ-
ated with the decision of whether or not to treat osteoporosis with
pharmacotherapy in clinical practice.2. Materials and methods
2.1. Study design
The design ofMUSICOS-AP is shown in Fig. 1. Details of the design of
MUSIC OS are given in the publication describing the closely related
MUSIC OS-EU study, which was carried out in Canada and Europe
(Modi et al., 2015). Like the EU study,MUSICOS-AP included three com-
ponents: a physician questionnaire, a retrospective chart review, and a
prospective cohort study. Sites were selected for participation in the
study based on their responses to the Site Assessment Questionnaire
and in such a way that their distribution was representative of real
world clinical practice for osteoporosis in each country. Factors such as
the investigator's experience in conducting clinical research, interest
in participation, and ability to dedicate time and resources to the
study were considered. Site investigators completed the physician
questionnaire and retrospective review of patients' charts. All sites
completed ethics reviews according to their local ethics board re-
quirements. Patients fulﬁlling the selection criteria were allocated
to either the treated or untreated patient group of the prospective
cohort study. Baseline assessments were conducted for all patients
at the enrollment visit, while follow-up questionnaires were com-
pleted only by treated patients at 3, 6, and/or 12 months after enroll-














Retrospective chart reviewb √
Informed consent and eligibility √
Demographics and risk factors for
osteoporosis
√
Osteoporosis disease assessment √
Medical history √
Bone mineral density test/T-scorec √ √ √ √
Participant treatment concernsd √ √ √ √
Medications (osteoporosis, GI, vitamin D
and calcium)e
√ √ √ √
Gastrointestinal events √ √ √ √
Healthcare resource utilization
questionnaire
√ √ √ √
ADEOS adherence scalea √ √ √ √
Treatment satisfaction questionnaire for
medications (OPSAT-Q)a
√ √ √
Health related quality of life (EQ-5D-3L) √ √ √
Health related quality of life (OPAQ-SV) √ √ √
New falls and fractures √ √ √
Adverse eventsc √ √ √
ADEOS, Adherence Evaluation of Osteoporosis treatment; EQ-5D-3L, European Quality of
Life-5 Dimensions; GI, gastrointestinal; OPAQ-SV, Osteoporosis Assessment Question-
naire; OPSAT-Q, Osteoporosis Patient Satisfaction Questionnaire.
a Not collected for untreated participants. Study completion/prematurediscontinuation
form was collected for all treated participants. If participant discontinued prior to 12
month follow-up visit, the reason for discontinuation, including death and death date (if
applicable), was recorded.
b The physician questionnaire and retrospective chart review were completed prior to
the commencement of the prospective component of the study. Physician questionnaire
was completed by the Principal Investigator at all sites. The retrospective chart review
was completed by a randomly selected subset of sites.
c Collected by the physician during any clinical ofﬁce visit, if applicable.
d Collected for untreated and treated participants at baseline and for treated patients
thereafter.
e At baseline, all applicable medications were recorded, while during follow-up only
those medications that had been changed or discontinued were recorded.
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The physician questionnaire collected information regarding the
physician's standard practices regarding the diagnosis and treatment
of patients with osteoporosis and his or her perspective on current oste-
oporosis treatment approaches and medication adherence. Treatment
approaches were examined speciﬁcally with regards to the manage-
ment of patients with GI events by asking how often physicians
witnessed GI events (e.g., heartburn, upset stomach, nausea, or pain)
and how often GI sensitivity impacted their decision to prescribe osteo-
porosis treatment and their choice ofmedication. Physicianswere asked
about their treatment strategies (e.g., prescribe a gastroprotective
agent, recommend a drug holiday, or switch to another medication)
with patients who either had pre-existing GI problems or developed
GI problems while taking osteoporosis therapy.
2.3. Retrospective chart review
In the retrospective chart review, the questions were limited to
whether the patient was receiving pharmacologic therapy—oral or
injected, calciumand/or vitaminD, or none—for their osteoporosis. Phy-
sicians from 26 randomly selected sites answered the questions on be-
half of their most recent patients.
2.4. Prospective cohort study
The prospective cohort component of this study enrolled both un-
treated and treated patients. Eligibility and exclusion criteria were the
same as in the MUSIC OS-EU study (Modi et al., 2015). Brieﬂy, patients
were eligible for enrollment in the prospective cohort study if they
were postmenopausalwomen, at least 50 years of age, had osteoporosis
in their physician's judgment (with or without a BMD test), and provid-
ed informed consent. Patients were excluded if they had been diag-
nosed with Parkinson's disease or any other neuromuscular disease or
Paget's disease; were currently treated with any injected medication
for osteoporosis; had been switched between oral pharmacologic oste-
oporosis medications within the past 3 months; or were currently or
formerly (past 90 days) enrolled in a clinical trial.
The untreated study arm comprised amaximumof 300 participants.
Simultaneously, a maximum of 3300 participants with osteoporosis
whowere receiving oral pharmacologic agents were targeted for enroll-
ment in the treated group. Pharmacologic treatments included
bisphosphonates (e.g., alendronate, risedronate, and ibandronate), cal-
citonin, strontium ranelate, and selective estrogen-receptormodulators
(raloxifene and bazedoxifene). Calcium and/or vitamin D and estrogen
and/or hormone replacement therapy were considered supplemental
to pharmacologic therapy. Treated participants were further classiﬁed
as new users or experienced users, deﬁned respectively as patients
who had been receiving oral pharmacologic therapy for less than 3
months and patients receiving the same oral pharmacologic therapy
for at least 3 months prior to enrollment.
Untreated patients completed only the baseline survey (Table 1).
Demographics, risk factors for osteoporosis, fracture history, medical
history, osteoporosis medications, bone mineral density (BMD) test re-
sults (T-scores), and vitamin D/calcium use were documented, as were
reasons for non-treatment and GI events in the prior 6 months. In addi-
tion, health care resource utilization in the prior 3 months, and quality
of life over the prior 2 weeks, were assessed.
Treated study participants completed the baseline survey and were
then followed for 12 months. Data collected at baseline only were: pa-
tient demographics, risk factors for osteoporosis, fracture history, med-
ical history, osteoporosis medications, BMD test results (T-scores), and
vitamin D/calcium use. Patient-reported outcomes collected at baseline
and all follow-up visits includedGI events, health care resource use, and
medication adherence. Health-related quality of life, treatmentsatisfaction, and adverse events were assessed in treated patients at
follow-up visits according to the schedule shown in Table 1.
GI events were deﬁned as the following clinical symptoms: heart-
burn/acid reﬂux, upset stomach/indigestion, nausea/vomiting, pain be-
hind the breastbone, pain on swallowing or food sticking, stomach pain
above or below the navel, diarrhea or constipation, and bloating. Gener-
al health-related and osteoporosis-speciﬁc quality of lifeweremeasured
by the European Quality of Life-5 Dimensions (EQ-5D-3 L) question-
naire (Oemar & Oppe, n.d.) and the Osteoporosis Assessment Question-
naire (OPAQ-SV) (Randell et al., 1998), respectively. Patient-reported
health care resource use was categorized as hospitalizations, fractures,
surgeries, or visits to a general practitioner, specialist, or emergency de-
partment in the preceding 3–6 months. Medication adherence was mea-
sured by the Adherence Evaluation of Osteoporosis treatment (ADEOS)
questionnaire (Breuil et al., 2012), and treatment satisfaction by theOste-
oporosis Patient Satisfaction Questionnaire (OPSAT-Q) (Flood et al.,
2006). Untreated participants did not complete the ADEOS or OPSAT-Q
questionnaires. Changes in osteoporosis medications (new medications
and medication discontinuations), occurrences of new falls, fractures,
and adverse events were also recorded at the follow-up visits.
All questionnaires were made available in the local language of the
participating clinics, as follows: in Australia and New Zealand, English;
in Korea, Korean; in Taiwan, traditional Chinese; and in India, Bengali,
Gujarati, Hindi, Kannada,Marathi, Tamil, Telugu, or English (as needed).
The translations of the self-administered and telephone versions of the
EQ-5D-3L questionnaire were supplied by Euroqol andwere certiﬁed as
linguistically validated. However, the face-to-face questionnaire was
not available in all languages needed for this study, so it was translated
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their standard guidelines. Similarly, validated translations of the OPAQ-
SV, ADEOS, and OPSAT-Q questionnaires were not available for all lan-
guages included in this study. These questionnaires were translated
(forward and back) into the languages listed above and certiﬁed by a
qualiﬁed translation vendor. The translationswere not linguistically val-
idated due to timeline and budget constraints, but the authors/license
holders of the questionnaires approved the use of the translations for
the MUSIC OS-AP study.
2.5. Data collection and analysis
Patient recruitment and baseline data collection occurred between
July 2013 andAugust 2014. Study staff enrolled patients at routine ofﬁce
visits, obtained informed consent, and administered the baseline evalu-
ation. Treatedpatientswere providedwith themonth 3 follow-up ques-
tionnaire at the time of the baseline visit. Months 6 and 12
questionnaires were mailed to treated patients prior to their respective
follow-up dates, and site personnel called participants to remind them
when their questionnaires were due. Data were collected at each
study site and entered into a secure, internet-based Electronic Data Cap-
ture system (ClinStream™).
The anticipated analyses are descriptive and no a priori hypothesis is
proposed. Future publications will present analyses of baseline data
from the physician questionnaire and reasons for non-treatment
among untreated patients. Publications on the prospective component
of the study will describe outcomes such as GI events, health care
resource use, medication adherence, health-related quality of life, treat-
ment satisfaction, and adverse events. These patient-reported outcomes
will be assessed over time (baseline, 6 months, and 12 months) and
compared across patients with and without GI events. Least squares
mean differences between patients with and without GI events will be
adjusted for common covariates such as age, history of GI events,
new/experienced user status, body mass index, highest level of educa-
tion, age at menopause, predominant treatment, hours of physical exer-
cise per week, number of previous fractures, number of previous falls,
parental hip fracture, current smoking, glucocorticoid use, co-
morbidities, alcohol consumption ≥3 units per day, and country of resi-
dence. Assuming an attrition rate of 15%–20%, the proposed sample size
of 3300 treated participants was calculated to permit a ﬁnal evaluable
population of 2700 subjects. This was expected to be sufﬁcient for the
descriptive and exploratory analyses anticipated and to permit compar-
isons between patients with and without GI events..
3. Results
3.1. Physician questionnaire and retrospective chart review
Physicians from 59 sites agreed to participate in the study: 20 from
Australia/New Zealand, 15 from India, 15 from Korea, and 9 from
Taiwan (Table 2). The study site sample comprised 16 primary care
clinics and 43 specialty centers (Table 2). Physician specialties included
rheumatology, endocrinology, bonemineralogy, geriatrics, orthopedics,
and osteology. Physicians at all sites completed the physician question-
naire. Data for 300 patients from 26 sites were abstracted for the retro-




India Korea Taiwan Total
Total 20 15 15 9 59
Specialty center 9 14 13 7 43
Primary care clinic 11 1 2 2 16
Participated in retrospective
chart review
9 1 9 7 263.2. Prospective cohort study
All 59 sites participated in the prospective cohort study. A total of
3588 patients were enrolled in this component of the study.
3.2.1. Characteristics of untreated patients
The characteristics of the 301 untreated patients are presented in
Table 3. Untreated patients were, on average, 63.0 years of age. Thema-
jority of untreated patients (56%) were West Asian, with the rest of the
study population comprising East Asians (32%) and Caucasians
(12%).This group had a mean (SD) FRAX score of 5.8 (5.4), and 18% of
them reported having prior osteoporotic fractures.
3.2.2. Characteristics of treated patients
The 3287 treated patients included 1416 new users and 1871 expe-
rienced users (Table 3). Treated patients were, on average, 65.4 years of
age. The largest ethnic group in this study arm was East Asians (45%),
followed by West Asians (41%) and Caucasians (14%). Treated patients
had a mean (SD) FRAX score of 12.8 (12.5), and 22% of them had a
prior osteoporotic fracture.
4. Discussion
The MUSIC OS-AP study will address several areas in which
information about osteoporosis treatment in the Asia-Paciﬁc region
is lacking. One of these areas is the physician's perspective of the
management of osteoporosis and the factors, including GI events, asso-
ciated with the decision to treat osteoporosis. Complementary to this
will be the patient's perspective of pharmacologic management of
osteoporosis—speciﬁcally the reasons for non-treatment and satisfac-
tion with the selection of treatment. A single study from Korea reported
that composite scores on the OPSAT-Q were higher (better) in monthly
versus weekly bisphosphonate users, in non-smokers versus current or
past smokers, and in non-users versus users of acid-relatedmedications
(Oh et al., 2012). MUSIC OS-AP will provide data from Korea and other
Asia-Paciﬁc countries for comparisonwith these results, aswell as infor-
mation on how patient satisfaction changes over time and with the oc-
currence of GI events. Thiswill be theﬁrst-recorded data on these topics
for most of the countries involved.
Another area lacking data, and one of the primary emphases of
MUSIC OS-AP, is the role of GI events in the treatment of osteoporosis.
Two studies from Asia-Paciﬁc countries have shown that treatment of
osteoporosis with bisphosphonates resulted in esophageal injury. In a
nationwide case–control study in Taiwan, use of alendronate increased
the risk of upper GI bleeding (hazard ratio 1.32) and lower GI bleeding
(hazard ratio 1.84) in bothmen andwomen (Peng et al., 2014). In an en-
doscopy study of healthy postmenopausal Korean women, 10 out of 16
experienced mucosal damage after taking alendronate daily for two
weeks (Mok et al., 2013). The association of osteoporosis treatment
with mild GI events is less clear (Tseng et al., 2006), perhaps because
GI problems are common among adults in Asia-Paciﬁc countries
(Chang et al., 2012; Guarner et al., n.d.; Ghoshal et al., 2011), regardless
of whether they are being treated for osteoporosis. There is also little in-
formation from Asia-Paciﬁc countries about the association of GI events
with health care resource use and quality of life of osteoporosis patients.
MUSIC OS-AP will address these gaps by determining the rate of GI
events in treated and untreated patients and assessing the association
of GI events with treatment rates, treatment patterns, and other
patient-reported outcomes in osteoporotic postmenopausal women.
Distinctive features of MUSIC OS-AP are its use of a physician ques-
tionnaire to assess factors predictive of osteoporosis treatment, the in-
clusion of an untreated group to assess patient-reported reasons for
and clinical correlates of non-treatment, and its focus on the link be-
tween GI events and patient-reported outcomes. MUSIC OS-AP will ac-
quire data on several rarely addressed patient-reported outcomes,
including health care resource use, satisfaction with treatment, and
Table 3
Characteristics of patients enrolled in the prospective cohort component of MUSIC OS-APa.
Untreated patients (N = 301) Treated patients
New users (N = 1416) Experienced users (N = 1871) All patients (N = 3287)
Age, mean (SD) years 63.0 (9.3) 62.9 (9.5) 67.3 (9.0) 65.4 (9.5)
Age at menopause, mean (SD) yearsb 48.5 (4.8) 47.2 (5.6) 48.4 (5.1) 47.9 (5.4)
Race, n (%)c
Caucasian 36 (12%) 80 (6%) 374 (20%) 454 (14%)
East Asian 97 (32%) 372 (26%) 1107 (59%) 1479 (45%)
West Asians 167 (56%) 963 (68%) 389 (21%) 1352 (41%)
Other 0 (0%) 1 (0%) 0 (0%) 1 (0%)
Height, mean (SD) cm 154.7 (6.4) 153.6 (6.9) 154.5 (6.6) 154.1 (6.7)
Weight, mean (SD) kg 62.6 (12.5) 60.9 (11.8) 57.8 (10.9) 59.1 (11.4)
Highest level of education, n (%)
High school or less 203 (68%) 1067 (75%) 1333 (71%) 2400 (73%)
Non-university certiﬁcate or diploma 16 (5%) 47 (3%) 92 (5%) 139 (4%)
University degree or higher 73 (24%) 240 (17%) 347 (19%) 587 (18%)
Prefer not to answer 8 (3%) 62 (4%) 98 (5%) 160 (5%)
Physical exercise, mean (SD) hours/week 4.0 (4.1) 3.1 (4.7) 4.6 (5.3) 4.0 (5.1)
Hypothyroidism, n (%) 67 (22%) 204 (14%) 230 (12%) 434 (13%)
Mean FRAX score (SD)d 5.8 (5.4) 10.6 (11.1) 15.5 (13.7) 12.8 (12.5)
OP risk factors, n (%)
Alcohol use (≥3 units per day) 2 (1%) 5 (0%) 10 (1%) 15 (0%)
Current smoking 4 (1%) 14 (1%) 21 (1%) 35 (1%)
Glucocorticoid use 10 (3%) 36 (3%) 78 (4%) 114 (3%)
Parental hip fracture 18 (6%) 42 (3%) 140 (7%) 182 (6%)
Prior OP fractures 53 (18%) 225 (16%) 482 (26%) 707 (22%)
Rheumatoid arthritis 27 (9%) 103 (7%) 167 (9%) 270 (8%)
Secondary osteoporosis 18 (6%) 36 (3%) 127 (7%) 163 (5%)
cm, centimeter; kg, kilogram; OP, osteoporosis; SD, standard deviation.
a Two patients, one untreated and one experienced user, were excluded from this table because of missing data on GI events.
b One experienced user and one new user had missing data.
c Caucasian was deﬁned as European, Mediterranean, Middle Eastern, or North African Descent. East Asian was deﬁned as Chinese, Korean, Japanese, or Taiwanese. West Asian was
deﬁned as Indian or Pakistani. Other included only those identifying as New Zealand Maori.
d FRAX scores were recorded for 21, 89, 72, and 161 patients in the respective columns.
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a more relevant depiction of the rate of GI events among osteoporosis
patients than can be gleaned solely from chart reviews or claims data-
base analyses. Patient-reported measures, however, may be subject to
a reporting bias and to variations in patient compliance with study pro-
cedures. For example, at-home completion of the questionnaires may
not occur exactly during the time frame speciﬁed in the study.
One limitation of the study design is that patients were not required
to report the severity of the GI events; in fact, GI events typically consid-
ered severe (e.g., those involving bleeding or perforation) were not in-
cluded in the patient questionnaire. Another limitation is that the
retrospective chart review will reﬂect the percentage of patients pre-
scribed medication, not necessarily the percentage of patients who ﬁll
and subsequently take their medications. Finally, although the size of
MUSICOS-APwill allow it to detect the true rate of GI events and the im-
pact of GI events on persistencewith treatment, the inclusion ofwomen
from fundamentally different ethnic groups and cultures may limit the
applicability of the combined results. For this reason, country-speciﬁc
analyses will be a useful feature of subsequent publications.
In conclusion, MUSIC OS-AP will highlight the association of GI
events with the management of osteoporosis and with patient-
reported outcomes in developing and developed countries of the Asia-
Paciﬁc region. MUSIC OS-AP will enable determination of the rates of a
broad range of GI events among both treated and untreated patients,
and provide a clearer understanding of the association of GI events
with persistence with treatment, quality of life, treatment satisfaction,
and osteoporosis- and GI-related health care utilization.
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